259 related articles for article (PubMed ID: 29263218)
1. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
Hogstad B; Berres ML; Chakraborty R; Tang J; Bigenwald C; Serasinghe M; Lim KPH; Lin H; Man TK; Remark R; Baxter S; Kana V; Jordan S; Karoulia Z; Kwan WH; Leboeuf M; Brandt E; Salmon H; McClain K; Poulikakos P; Chipuk J; Mulder WJM; Allen CE; Merad M
J Exp Med; 2018 Jan; 215(1):319-336. PubMed ID: 29263218
[TBL] [Abstract][Full Text] [Related]
2. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
3. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.
Xiao Y; van Halteren AGS; Lei X; Borst J; Steenwijk E; de Wit T; Grabowska J; Voogd R; Kemps P; Picarsic J; van den Bos C; Borst J
Blood; 2020 Nov; 136(19):2188-2199. PubMed ID: 32750121
[TBL] [Abstract][Full Text] [Related]
5. Langerhans cell histiocytosis: Version 2021.
Gulati N; Allen CE
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):15-23. PubMed ID: 34105821
[TBL] [Abstract][Full Text] [Related]
6. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.
Gao XM; Li J; Cao XX
Cell Commun Signal; 2022 Dec; 20(1):195. PubMed ID: 36536400
[TBL] [Abstract][Full Text] [Related]
8. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells.
Lim KPH; Milne P; Poidinger M; Duan K; Lin H; McGovern N; Abhyankar H; Zinn D; Burke TM; Eckstein OS; Chakraborty R; Sengal A; Scull B; Newell E; Merad M; McClain KL; Man TK; Ginhoux F; Collin M; Allen CE
Blood Adv; 2020 Jan; 4(1):87-99. PubMed ID: 31899802
[TBL] [Abstract][Full Text] [Related]
9. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
[TBL] [Abstract][Full Text] [Related]
10. Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis.
Okamoto T; Murata Y; Hasegawa D; Yoshida M; Tanaka D; Ueda T; Hazama D; Oduori OS; Komori S; Takai T; Saito Y; Kotani T; Kosaka Y; Maniwa Y; Matozaki T
Cancer Sci; 2023 May; 114(5):1871-1881. PubMed ID: 36788737
[TBL] [Abstract][Full Text] [Related]
11. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?
Berres ML; Merad M; Allen CE
Br J Haematol; 2015 Apr; 169(1):3-13. PubMed ID: 25430560
[TBL] [Abstract][Full Text] [Related]
12. Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells.
Hutter C; Kauer M; Simonitsch-Klupp I; Jug G; Schwentner R; Leitner J; Bock P; Steinberger P; Bauer W; Carlesso N; Minkov M; Gadner H; Stingl G; Kovar H; Kriehuber E
Blood; 2012 Dec; 120(26):5199-208. PubMed ID: 23074278
[TBL] [Abstract][Full Text] [Related]
13. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.
Sahm F; Capper D; Preusser M; Meyer J; Stenzinger A; Lasitschka F; Berghoff AS; Habel A; Schneider M; Kulozik A; Anagnostopoulos I; Müllauer L; Mechtersheimer G; von Deimling A
Blood; 2012 Sep; 120(12):e28-34. PubMed ID: 22859608
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
Jouenne F; Benattia A; Tazi A
Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
[TBL] [Abstract][Full Text] [Related]
17. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
18. BRAF-V600E utilizes posttranscriptional mechanisms to amplify LPS-induced TNFα production in dendritic cells in a mouse model of Langerhans cell histiocytosis.
Minichino D; Lv K; Chu N; Tong W; Behrens EM
J Leukoc Biol; 2022 Nov; 112(5):1089-1104. PubMed ID: 35648675
[TBL] [Abstract][Full Text] [Related]
19. Langerhans cell histiocytosis.
Rodriguez-Galindo C; Allen CE
Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
[TBL] [Abstract][Full Text] [Related]
20. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
Tojo A; Kobayashi M
Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
